SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$42.38 USD
-0.43 (-1.00%)
Updated May 24, 2024 04:00 PM ET
After-Market: $42.34 -0.04 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 141 - 160 ( 188 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Competitor Agent Provides Proof of Concept for Lifirafenib + Mirdametinib; Raising to $73
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Fifth Nirogacestat Collaboration Agreement Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat - A Hat Trick of BCMA-targeted Combinations
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Belantamab Receives FDA Accelerated Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat Phase 3 DeFi Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Belantamab Receives Unanimous Recommendation for Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
FDA Questions Belantamab''s Risk/Reward Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Encouraging Preclinical Lifirafenib + Mirdametinib Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
BCMA Competitive Landscape Updates From ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
ASCO and AACR Data Updates Approaching; 1Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Mirdametinib + Lifirafenib Risk Mitigation via Competitor Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Adjusting Our Mirdametinib Pricing Assumptions Following Koselugo FDA Approval; Modulating PT to $58
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R